Therefore, the targeted drugs for HER2-positive breast cancer have evolved from single targeting (mAbs) to combination therapy and multi-mechanism innovation (chemotherapy, TKIs, ADC, bsAbs) for various indications. Here, ERBB2 is linked to breast cancer.